A proof-of-concept clinical trial design combined with dose-ranging exploration

Pharmaceutical Statistics

Volumn 11, Issue 5, 2012, Pages 403-409

  Wang, Xin ^a   Ting, Naitee ^b  

^a PFIZER INC   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

dose ranging; Emax; gatekeeping; proof of concept; trend test

Indexed keywords

ARTICLE; CLINICAL DEVELOPMENT PLAN; CLINICAL TRIAL (TOPIC); DOSE RANGING; DOSE RESPONSE; DRUG INDUSTRY; MATHEMATICAL MODEL; PATIENT REFERRAL; PROOF OF CONCEPT; SIMULATION; STUDY DESIGN; TREND STUDY;

CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; RESEARCH DESIGN; TIME FACTORS;

EID: 84866348849     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.1525     Document Type: Article

References (18)

1. Tamhane AC,. Statistical analysis of designed experiments: theory and applications. Wiley: Hoboken, New Jersey, 2009.
2. Dmitrienko A, Offen W, Westfall P,. Gatekeeping strategies for clinical trials that do not require all primary effects to be significant. Statistics in Medicine 2003; 22: 2387-2400. (Pubitemid 36949661)
3. MacDougall J,. Analysis of dose-response studies-Emax model. In Dose Finding in Drug Development, Ting N, (ed.). Springer, Berlin: New York, 2006; 127-145.
4. Thomas N,. Hypothesis testing and Bayesian estimation using a sigmoid Emax model applied to sparse dose-response designs. Journal of Biopharmaceutical Statistics 2006; 16 (5): 657-677. (Pubitemid 44844018)
5. Bretz F, Pinheiro JC, Branson M,. Combining multiple comparisons and modeling techniques in dose-response studies. Biometrics 2005; 61 (3): 738-748.
6. Dmitrienko A, Tamhane AC, Wang X, Chen X,. Stepwise gatekeeping procedures in clinical trial applications. Biometrical Journal 2006; 48 (6): 984-991.
7. Westfall PH, Krishen A,. Optimally weighted, fixed sequence, and gatekeeping multiple testing procedures. Journal of Statistical Planning and Inference 2001; 99: 25-40. (Pubitemid 33619467)
8. Maurer W, Hothorn L, Lehmacher W,. Multiple comparisons in drug clinical trials and preclinical assays: a-priori ordered hypotheses. In Biometrie in der chemisch-pharmazeutischen Industrie, Vollmar J, (ed.). Fischer Verlag: Stuttgart, 1995; 3-18.
9. Bauer P, Röhmel J, Maurer W, Hothorn L,. Testing strategies in multi-dose experiments including active control. Statistics in Medicine 1998; 17: 2133-2146. (Pubitemid 28442020)
10. Dmitrienko A, Wiens B, Westfall P,. Fallback tests in dose-response clinical trials. Journal of Biopharmaceutical Statistics 2006; 16 (5): 745-755. (Pubitemid 44844023)
11. Pinheiro JC, Bretz F, Branson M,. Analysis of dose-response studies-modeling approaches. In Dose Finding in Drug Development. Springer: New York, 2006; 146-171.
12. Cartwright ME, Cohen S, Fleishaker JC, Madani S, McLeod JF, Musser B, Williams SA,. Proof of concept: a PhRMA position paper with recommendations for best practice. Clinical pharmacology & Therapeutics 2010; 87 (3): 278-285.
13. Bretz F, Maurer W, Brannath W, Posch M,. A graphical approach to sequentially rejective multiple test procedures. Statistics in Medicine 2009; 28: 586-604.
14. Chang M, Chow SC,. Power and sample size for dose response studies. In Dose Finding in Drug Development, Ting N, (ed.). Springer, Berlin: New York, 2006; 220-241.
15. Efron B,. Bootstrap methods: another look at the jackknife. The Annals of Statistics 1979; 7: 1-26.
16. Moulton L, Zeger S,. Bootstrapping generalized linear models. Computational Statistics & Data Analysis 1991; 11: 53-63.
17. Ting N,. Practical and statistical considerations in designing an early phase II osteoarthritis clinical trial: a case study. Communications in Statistics-Theory and Methods 2009; 38 (18): 3282-3296.
18. Hamlett A, Ting N, Hanumara C, Finman JS,. Dose spacing in early dose response clinical trial designs. Drug Information Journal 2002; 36 (4): 855-864. (Pubitemid 36417246)